Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names

You may also be interested in...



Asia Spotlight: Merck In Multiple Partnerships To Finance Hep C Treatment In India

Merck’s Indian arm MSD India has linked up with a financial institution and is considering national rollout of a funding plan that aims to stretch the cost of hepatitis C treatment over several months. The impact could mean that up to about 45% of the affected population might get treatment, up from 3% now.

Exclusive: Merck In Multiple Partnerships To Finance Hep C Treatment In India

In what could perhaps be the first such experiment in the Indian pharmaceutical industry, Merck’s Indian arm MSD India has linked up with a financial institution and is considering a national rollout of a funding plan that aims to expand the cost of hepatitis C treatment over several months, thereby easing the burden on needy patients. The bigger gain could mean that from just 3% of the population that get treated for the fatal disease the number could swell to roughly 45% of the population.

A Closer Look At Merck's Commercial Restructuring: What Happened To India?

In the latest overhaul of its commercial operations, Merck shared enthusiasm about prospects in emerging markets. But it did not include India, Turkey and Poland in its list of top 10 priority markets, a change from its vision shared just four years ago

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel